p.43 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

September 16, 2025 Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 e156

Antihypertensive Medication Class Combination Medication Combination Generic Available Doses Available (in Order of Medication Combination Listed)

Perindopril + amlodipine No (est. patent expiration 2029) 3.5 mg/2.5 mg

7 mg/5 mg 14 mg/10 mg

Trandolapril + verapamil Yes 1 mg/240 mg

2 mg/180 mg 2 mg/240 mg 4 mg/240 mg

Olmesartan + amlodipine Yes 20 mg/5 mg

20 mg/10 mg 40 mg/5 mg 40 mg/10 mg

Telmisartan + amlodipine Yes 40 mg/5 mg

40 mg/10 mg 80 mg/5 mg 80 mg/10 mg

Valsartan + amlodipine Yes 160 mg/5 mg

160 mg/10 mg 320 mg/5 mg 320 mg/10 mg

ARB + Beta blocker Valsartan + nebivolol Yes 80 mg/5 mg Beta blocker + Thiazide-type diuretics Atenolol + chlorthalidone Yes 50 mg/25 mg

100 mg/25 mg

Bisoprolol + HCTZ Yes 2.5 mg/6.25 mg

4 mg/6.25 mg 10 mg/6.25 mg

Metoprolol tartrate + HCTZ Yes 50 mg/25 mg

100 mg/25 mg 100 mg/50 mg

Potassium-sparing diuretic + thiazide-type diuretics Amiloride + HCTZ Yes 5 mg/50 mg

Triamterene + HCTZ Yes 37.5 mg/25 mg

75 mg/50 mg

MRA + thiazide-type diuretics Spironolactone + HCTZ Yes 25 mg/25 mg ARB + CCB + thiazide-type diuretics Olmesartan + amlodipine + HCTZ Yes 20 mg/5 mg/12.5 mg

40 mg/5 mg/12.5 mg 40 mg/5 mg/25 mg 40 mg/10 mg/12.5 mg 40 mg/10 mg/25 mg

Valsartan + amlodipine + HCTZ Yes 160 mg/5 mg/12.5 mg

160 mg/5 mg/25 mg 160 mg/10 mg/12.5 mg 160 mg/10 mg/25 mg 320 mg/10 mg/25 mg

Data are derived from the FDA Orange Book databases.18 ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; FDA, Food and Drug Administration; HCTZ, hydrochlorothiazide; and MRA, mineralocorticoid receptor antagonist.

Table 14.  Continued

Downloaded from http://ahajournals.org by on October 7, 2026